The Regional-Specific Relative and Absolute Expression of Gut Transporters in Adult Caucasians: A Meta-Analysis^S

Matthew D. Harwood, Mian Zhang, Shriram M. Pathak,¹ and Sibylle Neuheoff

Certara UK Ltd., Simcyp Division, Sheffield, United Kingdom

Received March 15, 2019; accepted April 30, 2019

ABSTRACT

The aim of this study was to derive region-specific transporter expression data suitable for in vitro-to-in vivo extrapolation (IVIVE) within a physiologically based pharmacokinetic (PBPK) modeling framework. A meta-analysis was performed whereby literary sources reporting region-specific transporter expression obtained via absolute and relative quantification approaches were considered in healthy adult Caucasian individuals. Furthermore, intestinal total membrane protein yield was calculated to enable mechanistic IVIVE via absolute transporter abundances. Where required, authors were contacted for additional information. A refined database was constructed where samples were excluded based on quantification in, non-Caucasian subjects, disease tissue, subjects <18 years old, duplicated samples, non-total membrane matrix, pooled matrices, or cDNA. Demographic data were collected where available. The weighted and geometric mean, coefficient of variation, and between-study homogeneity was calculated in each of eight gut segments (duodenum, two jejunum, four ileum, and colon) for 16 transporters. Expression data were normalized to that in the proximal jejunum. From a total of 47 articles, the final database consisted of 2238 measurements for 16 transporters. The solute carrier peptide transporter 1 (PepT1) showed the highest jejunal abundance, while multidrug resistance-associated protein (MRP) 2 was the highest abundance ATP-binding cassette transporter. Transporters displaying significant region-specific expression

included the ileal bile acid transporter, which showed 18-fold greater terminal ileum expression compared with the proximal jejunum, while MRP3, organic cation transporter type 1 (OCTN1), and OCT1 showed >2-fold higher expression in other regions compared with the proximal jejunum. This is the first systematic analysis incorporating absolute quantification methodology to determine region-specific intestinal transporter expression. It is expected to be beneficial for mechanistic transporter IVIVE in healthy adult Caucasians.

SIGNIFICANCE STATEMENT

Given the burgeoning reports of absolute transporter abundances in the human intestine, the incorporation of such information into mechanistic IVIVE-PBPK models could offer a distinct advantage in facilitating the robust assessment of the impact of gut transporters on drug disposition. The systematic and formal assessment via a literature meta-analysis described herein, enables assignment of the regional-specific expression, absolute transporter abundances, interindividual variability, and other associated scaling factors to healthy Caucasian populations within PBPK models. The resulting values are available to incorporate into PBPK models, and offer a verifiable account describing intestinal transporter expression within PBPK models for persons wishing to utilize them. Furthermore, these data facilitate the development of appropriate IVIVE scaling strategies using absolute transporter abundances.

Introduction

Physiologically based pharmacokinetic (PBPK) models are increasingly being employed in making key decisions on the clinical progress of

new chemical entities (NCEs) in drug development and regulatory spheres (Shebley et al., 2018). A growing assurance in the ability to predict the pharmacokinetics, pharmacodynamics, and drug-drug interactions of NCEs within virtual individuals built into PBPK models has been based on the continued dedication of allied academic, industrial, and regulatory institutions to develop robust physiologic parameters that are essential in facilitating the generation of relevant individuals within virtual populations. Alongside this, the development of mechanistic strategies that harness data generated from in vitro assays routinely performed to characterize the NCE pharmacokinetic liability via in vitro-to-in vivo extrapolation (IVIVE) strategies is critical in enabling insightful judgments regarding clinical progress being made. For several years now, the capacity to scale cytochrome P450 (P450) activities via recombinant in vitro systems and absolute protein expression has been

This research was funded by Certara UK Ltd. (Simcyp Division).

This work was presented as a conference proceeding [Abstract and Poster (208)] at the 21st North American ISSX Meeting, September 2017, Providence, RI. The title of the Abstract was “Abundance & relative segmental expression of intestinal transporters in caucasians: a meta-analysis.” This can be viewed at the following website: <http://issx.confex.com/issx/21NA/webprogram/Paper37982.html> and in *Drug Metabolism and Pharmacokinetics* 33(1):S88–S89 DOI: 10.1016/j.dmpk.2017.11.289.

¹Current affiliation: Quotient Sciences, Nottingham, United Kingdom.

<https://doi.org/10.1124/dmd.119.086959>.

^SThis article has supplemental material available at dmd.aspetjournals.org.

ABBREVIATIONS: ADAM, advanced dissolution absorption and metabolism; GLUT2, glucose transporter 2; IBAT, ileal bile acid transporter; ISEF-T, intersystem extrapolation factor for transporters; IVIVE, in vitro-to-in vivo extrapolation; M-ADAM, multilayer advanced dissolution absorption and metabolism; MDR1, multidrug resistance protein 1; MRP, multidrug resistance-associated protein; NCE, new chemical entity; OATP, organic anion transporting polypeptide; OCT, organic cation transporter; OST, organic solute transporter; P450, cytochrome P450; PBPK, physiologically based pharmacokinetic; PCR, polymerase chain reaction; PepT1, peptide transporter 1; P-gp, P-glycoprotein; REF, relative expression factor; TM, total membrane; TMePPC, total membrane protein per colon; TMePPI, total membrane protein per intestine.

demonstrated in the intestine (Gertz et al., 2010). Historically, the availability of protein standards employed within assays to quantify P450 absolute protein abundances in both in vitro systems and mammalian tissues has facilitated the development of such strategies. These approaches are underpinned by incorporating scaling factors that act to bridge any mechanistic gaps between the in vitro and in vivo milieu, and are typically based on determining the relative expression (or activity) or the difference in functional protein abundance between the in vivo and in vitro systems (Proctor et al., 2004). In particular, an expanding body of evidence has meant that judgments on the clinical progress of NCEs for certain P450-mediated drug-drug interactions can be reached by harnessing PBPK modeling strategies that predict its pharmacokinetic/drug-drug interaction liabilities (Jones et al., 2015; Wagner et al., 2015; de Zwart et al., 2016; Shebley et al., 2018). Furthermore, regulatory authorities have been developing guidance to ensure rigorous quality assurance is applied to NCE submissions that harness mechanistic PBPK modeling (<https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM531207.pdf>; http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/07/WC500211315.pdf).

Since protein standards historically have not been routinely available for membrane transporter expression absolute quantification, the capacity to scale transporter activity by IVIVE in order to predict the impact of transporter-mediated drug clearance within specific organs of a PBPK model has relied on transporter expression data from relative quantification approaches, i.e., mRNA expression quantification via reverse transcription polymerase chain reaction (PCR) or protein expression from immunoblotting to derive and apply relevant scaling strategies (Harwood et al., 2013; Neuhoﬀ et al., 2013), while other related transporter IVIVE-PBPK models have required additional empirical scalars to ensure the model captures the clinical observations (Jones et al., 2012; Varma et al., 2012; Jamei et al., 2014). Recently, we undertook and reported on an extensive literature meta-analysis to establish 19 transporter protein abundances in the healthy Caucasian liver (Burt et al., 2016). Accompanying the meta-analysis was the development of an IVIVE strategy to harness interindividual variability in hepatic absolute transporter abundances (in picomoles) determined via the meta-analysis by using a unitless intersystem extrapolation factor for transporters (ISEF-T) within IVIVE. The drive to develop this strategy was the following: 1) a desire within the industry to develop more mechanistic scaling factors to facilitate model development for transporter IVIVE (Jones et al., 2015; Pan et al., 2016; Guo et al., 2018), and 2) the literary reporting of absolute transporter protein abundances in human livers utilizing burgeoning proteomics techniques (Heikkinen et al., 2015).

The capacity to scale transporter activity data obtained in relevant in vitro cell monolayers within PBPK models that describe region-specific intestinal transporter expression levels based on relative expression approaches has been demonstrated for intestinal efflux transporters such as P-glycoprotein (P-gp) (Neuhoﬀ et al., 2013; Yamazaki et al., 2018). However, by building on the incorporation of absolute transporter abundance scaling of hepatic transporter activity (i.e., the ISEF-T approach), our aim was to perform an extensive meta-analysis of the expanding human intestinal transporter absolute abundance quantification literature in order to facilitate the development of an ISEF-T approach to scale transporter activity data in and along the gut. Furthermore, an appraisal of the literature utilizing relative quantification approaches was undertaken to determine region-specific expression of gut transporters, which could then be assimilated with that of absolute quantification-based studies. A similar rigor was applied to the gut transporter abundance meta-analysis as was done for that of the liver in terms of study exclusion criteria (Burt et al., 2016). We provide a

meta-analysis of quantitative intestinal transport abundance data to employ the ISEF-T approach in IVIVE-PBPK.

Methods

Priming the Database: Identifying and Prioritizing Intestinal Transporters for Analysis. There are more than 400 transporter genes identified in the human genome (César-Razquin et al., 2015). Therefore, prior to undertaking a systematic meta-analysis to establish region-specific transporter expression in the human intestine, it was important to primarily identify and prioritize transporter isoforms that show demonstrable expression in the human small and large intestines and possess the capacity to interact with drugs to potentially influence drug disposition. Based on analysis of the literature (via searching the PubMed electronic database; <https://www.ncbi.nlm.nih.gov/pubmed>), a database comprising 52 transporters relevant to the human intestine was collated, in which evidence was gathered and recorded on the transporter isoform(s) human intestinal expression and the methodology employed to quantify expression: membrane localization (apical, basolateral, or both), transporter function (i.e., uptake, efflux, or both), in vivo (human clinical) and in vitro evidence (cell monolayer studies) of interaction with drugs (substrate/inhibitor moieties), regulatory requirement/interest (i.e., the US Food and Drug Administration and European Medicines Agency), and focused groups such as the International Transporter Consortium. Given the available evidence, the transporters were ranked based on criteria such as robust evidence of mRNA transcription, protein expression, or known to be involved in intestinal drug absorption/disposition. Ultimately, the 16 highest ranked transporters were identified and are summarized in Table 1, including 10 transporters from the solute carrier family and six transporters from the ATP-dependent binding cassette superfamily, which were then prioritized for subsequent electronic literature searches and integration into an abundance database for meta-analysis.

Transporter Abundance Database. A single overarching complete database was collated to contain published abundance data for the 16 prioritized transporters quantified in human intestinal tissue. The complete database included separate data sets, where the quantification of transporter abundances was performed using either absolute or relative approaches. Absolute transporter abundance data were typically quantified against a standard curve of a verified surrogate peptide(s) using quantitative targeted proteomics via liquid chromatography–tandem mass spectrometry or a quantitative western blot approach. In these assays, the transporter protein abundance is expressed in moles per mass of protein. For the relative transporter abundance data, quantification was typically performed using PCR or immunoblotting technology, where the abundance of the transporter was expressed relative to a housekeeper gene or protein. Original research articles were retrieved via searching the PubMed electronic database using combinations of the following keywords: human, intestinal, transporter, absolute, relative, protein, expression, abundance, and proteomics. The database including all available measurements was established (final literature search June 2017), with background information on the methods as well as donor demographics collated where provided. In cases where individual data were not directly reported, data were extracted via GetData Graph Digitizer (version 2.22, <http://getdata-graph-digitizer.com>) or authors were contacted directly to request individual donor data. A refined subdatabase was created through the use of various exclusion criteria. First, study methodologies were reviewed to ensure that absolute abundances were quantified using liquid chromatography–tandem mass spectrometry or quantitative western blot in total membrane (TM) fractions. For relative expression studies the same stringency for quantification in a TM fraction was not appropriate since numerous

TABLE 1

The 16 transporters selected for inclusion into the meta-analysis after exclusion criteria were applied to determine region-specific transporter expression in the ADAM and M-ADAM models

Protein	Membrane Localization	Functionality	Quantification (Relative/Absolute) ^a
SLC10A2 (IBAT)	Apical	Uptake	Relative and absolute
SLC15A1 (PEPT1)	Apical	Uptake	Relative and absolute
SLC16A1 (MCT1)	Apical	Uptake	Relative
SLCO2B1 (OATP2B1)	Apical	Uptake	Relative and absolute
SLC22A1 (OCT1)	Apical	Uptake	Relative and absolute
SLC22A3 (OCT3)	Apical	Uptake	Relative and absolute
SLC22A4 (OCTN1)	Apical	Uptake	Relative
ABCB1 (P-gp)	Apical	Efflux	Relative and absolute ^b
ABCC2 (MRP2)	Apical	Efflux	Relative and absolute ^b
ABCG2 (BCRP)	Apical	Efflux	Relative and absolute ^b
SLC2A2 (GLUT2)	Basolateral ^c	Uptake	Relative
SLCO4C1 (OATP4C1)	Basolateral ^c	Uptake	Relative
SLC51A/B (OST- α/β)	Basolateral ^c	Efflux	Relative and absolute ^d
ABCC1 (MRP1)	Basolateral ^c	Efflux	Relative
ABCC3 (MRP3)	Basolateral ^c	Efflux	Relative and absolute
ABCC4 (MRP4)	Basolateral ^c	Efflux	Relative

BCRP, breast cancer resistance protein; MCT1, monocarboxylate transporter 1; PEPT1, peptide transporter 1.

^aRelates to data available and collated in the final database (i.e., without exclusion criteria applied) (see Fig. 1) for a transporter.

^bA substantial meta-analysis for relative expression of P-gp, MRP2, and BCRP had already been performed, and the results are published in Harwood et al. (2013).

^cNote that the M-ADAM model requires selection to enable activation of the basolateral membrane localized transporters.

^dData collated distinctly for α (SLC51A) and β (SLC51B) subunits, hence counted as individual transporters in the Fig. 1 count of transporter data collated.

studies were included that required mRNA extraction and subsequent reverse transcription to cDNA for PCR-based expression quantification. Next, data in which it was stated that the human intestinal tissue was not from adult (aged <18 years), healthy (or macroscopically normal after histologic assessment), or Caucasian individuals were excluded. Any study in which pooling of sample matrices took place for mRNA, cDNA (Herrera-Ruiz et al., 2001; Seward et al., 2003), or microsomal samples for protein absolute abundance analysis (Nakamura et al., 2016) was not included since interindividual variability is lost when pooling as only mean with experimental error/deviation is, therefore, available. However, such data sets can be used to compare the results of meta-analyzed expression data of relevant transporters. For the relative expression studies, any study that did not normalize the target (i.e., transporter) gene or protein against a reference (or housekeeper gene/protein) within the same assay was excluded (Landowski et al., 2003; Kim et al., 2007). Exclusion occurred in instances where there was relative quantification of a transporter in a single region of the intestine (Hilgendorf et al., 2007) in which quantification only took place in the jejunum, hence normalization to other segments could not take place (see the procedural aspects given in *Data Analysis: Determining Region-Specific Intestinal Transporter Expression via Meta-Analysis of Meta-Analysis*). Finally, the sources of data were identified to ensure that duplicate measurements from the same tissue sample were not included in the refined database. Meta-analysis was then used to characterize the region-specific abundance of intestinal transporters in the refined database.

Data Analysis: Determining Region-Specific Intestinal Transporter Expression via Meta-Analysis. Within the Simcyp Simulator the advanced dissolution absorption and metabolism (ADAM) and multilayer ADAM (M-ADAM) models, which constitute seven small intestinal segments (one duodenum, two jejunum, and four ileum segments) and a single segment representing the colon, contain the transporter expression specific to each intestinal segment (Jamei et al., 2009). The region-specific transporter expression is normalized relative to the proximal jejunum segment (jejunum I), as was previously described for *ABCB1* (P-gp), *ABCC2* [multidrug resistance-associated protein (MRP) 2], and *ABCG2* (breast cancer resistance protein) using relative quantification approaches (Harwood et al., 2013). Hence, the

meta-analysis was structured to take into account quantification of transporter abundance in each segment of the ADAM and M-ADAM models. Where there was insufficient information described in the study—for example, where samples were described as from the ileum and not described with greater precision to a specific region of the ileum—the expression data for that study were assigned with those expression values to each of the four ileum segments constituting ADAM and M-ADAM.

The meta-analysis comprised three data sets: 1) region-specific abundances determined from absolute abundance data, 2) region-specific abundances determined from relative expression data, and 3) region-specific abundances determined from a combination of absolute and relative data. For the meta-analysis, the region-specific abundances were determined after normalization to the weighted mean abundances in the reference segment of the proximal jejunum (i.e., jejunum I) (Harwood et al., 2013). For the relative abundance measurements that did not contain a jejunum sample, the values were initially scaled to colon or ileum and the relative average value was later used to combine all data relative to jejunum I.

In line with the previous meta-analysis (Harwood et al., 2013), where studies differentiated between colonic regions the transporter expression data were incorporated into the final analysis from those samples originating from the ascending colon, and where no suitable absolute abundance quantification data were available for a transporter, a jejunum I absolute abundance value of zero (in picomoles per milligram TM protein) was assigned. The meta-analysis proceeded to establish the region-specific abundance levels of that transporter based on relative transporter quantification methodology, where quantification was undertaken in the jejunum; therefore, normalization to jejunum I could be performed. In instances where abundance data generated via absolute or relative quantification methods were available for a transporter, the databases were combined within the meta-analysis framework.

After applying the exclusion criteria to the complete database, the collated abundance values for the healthy, Caucasian adult sub-database were combined for a given transporter to generate the weighted mean, geometric mean, S.D. and CV for the jejunum I segment of the extensive transporter (representing the wild type) phenotype based on the

equations described previously for metabolizing enzymes (Perrett et al., 2007). The abundance values were further tested for between-study heterogeneity using the Cochran X^2 -based Q test (Perrett et al., 2007), whereby heterogeneity was apparent when a probability of $P < 0.05$ was returned.

The assigned CV was preferentially based on absolute abundance data when these were available for a transporter isoform, while for the majority of the other transporters analyzed, a CV based on relative expression data was required since absolute data were either not available or were excluded based on the aforementioned criteria. For *SLC51A/B* [organic solute transporter (OST)- α/β] and *SLC10A2* [ileal bile acid transporter (IBAT)], additional considerations for CV determination were required. The rationale for their derivation is described in *Results: Absolute Abundance Data Analysis*, where unless otherwise stated the mean is provided in the text as mean $\pm$ S.D. for the abundance values (in picomoles per milligram of TM protein).

Total Membrane Protein Yield in the Small intestine and Colon. To facilitate the scaling of in vitro activity data per picomole of transporter to the entire small intestine and colon requires that the human intestinal abundances, as determined in the aforementioned meta-analysis, are converted to picomoles per intestinal segment, thus enabling the calculation of segmental transporter activity (clearance). Since the meta-analysis of human intestinal abundances incorporated values reported as picomoles per milligram of TM protein, we sought to determine the small intestinal and colonic total membrane protein yield in milligrams.

Literature sources that specifically reported total membrane protein per intestine (TMePPI), which is related to small intestinal yield, and total membrane protein per colon (TMePPC) were sought. For each study, the TM protein yield for the specific intestinal segment from which the TM fractions were obtained was scaled to the duodenum, jejunum, and ileum dependent on the procedure, i.e., mucosal scraping (Tucker et al., 2012), mucosal crushing (Drozdik et al., 2014), or enterocyte elution (Harwood, 2015). In instances where procedural losses during preparation of TM protein from tissue homogenates were available, these were taken into account in the final segmental yield

calculations. The weighted mean values of the TMePPI and TMePPC are given in milligrams. The specific methodologies used to obtain segmental TM protein yield from each study are provided in the Supplemental Material in the section on the total membrane protein yield.

Results

Abundance Database. In this study, a total of 47 articles were recorded in the complete database of which 30 were accepted into the meta-analysis after exclusion criteria were applied. The complete database consisted of 3374 absolute and relative quantification measurements of transporter expression (see Supplemental Tables 2A and 2B for studies and sample quantification information). Of this complete database, 2238 relative- and absolute-based quantification measurements across all intestinal regions for 16 transporters matched our inclusion criteria and were thus included in the final data set for adult healthy Caucasians (Fig. 1). The final absolute database consisted of five independent studies (Tucker et al., 2012; Gröer et al., 2013; Oswald et al., 2013; Drozdik et al., 2014; Harwood et al., 2015), and data from a Ph.D. program published in a thesis (Harwood, 2015), with the data linked to that published in Harwood et al. (2015). The most common reason for the exclusion of absolute abundance data was the use of samples from individuals with underlying disease conditions (40%), whereas for the relative abundance it was data from non-Caucasian samples (12%). Other reasons for exclusion of absolute abundance data were the reporting of data from duplicate samples (Brück et al., 2017) and quantification in samples other than TM fractions (9% of complete absolute database) (Wiśniewski et al., 2015; Vaessen et al., 2017), while the other criteria for exclusion in both the absolute and relative data sets constituted a relatively minor component (Fig. 1; Supplemental Table 1). There was limited information available on an individual's phenotype status; therefore, no studies were excluded for possessing nonextensive-transporter phenotype samples. The samples quantifying absolute abundances and excluded due to underlying disease were due to individuals who were morbidly obese with a body mass index >30

Fig. 1. Exclusion criteria applied to the complete database for the absolute (left) and relative (right) abundance data. Percentages for each exclusion criterion refer to the fraction of the samples in the complete database that were excluded on its basis.

(Miyauchi et al., 2016) and those samples classified as possessing adenoma or cancer (Wiśniewski et al., 2015), while for the relative abundance quantifications, Crohns and ulcerative colitis samples (Thibault et al., 2007) required that these were excluded from the refined database. Non-Caucasian ethnicity samples were excluded since they incorporated abundance data from Japanese individuals (Hinoshita et al., 2000; Terada et al., 2005).

Of the 16 transporters on which the final meta-analysis was based (Table 1), suitable absolute data could not be obtained for six transporters at the time of this meta-analysis due to one or more of the criteria outlined in Fig. 1. These transporters were *SLC16A1* (monocarboxylate transporter 1), *SLC22A4* [organic cation transporter (OCT), type 1 (OCTN1)], *SLC2A2* [glucose transporter 2 (GLUT2)], *ABCC1* and *ABCC4* (MRP1 and MRP4, respectively), and *SLCO4C1* [organic anion transporting polypeptide (OATP) 4C1]. Where absolute abundance data were not available for any transporter, the relative quantification data were used to determine the region-specific abundance in the intestine.

Absolute Abundance Data Analysis. A summary of the absolute abundances for the 10 transporters in the healthy Caucasian adult proximal jejunum, assigned as jejunum I in the ADAM model, is provided in Table 2. The solute carrier apical uptake carrier peptide transporter 1 (PepT1) showed the highest abundance in the human jejunum I samples with a weighted mean abundance of 3.69 ± 1.5 pmol/mg TM protein ($n = 11$). The highest abundance the ATP-binding cassette transporter was MRP2 with 0.86 ± 0.58 pmol/mg TM protein ($n = 11$). In this analysis, the mean jejunum I abundance for OST- α/β was taken from analysis of distal rather than proximal jejunum due to the lack of quantification in proximal jejunum regions. OST- α/β is a dimeric protein conferring functionality when both α and β subunits coalesce (Seward et al., 2003). However, absolute quantification methods typically endeavor to quantify the abundance of each subunit separately (Harwood, 2015). For this analysis, the α subunit was used for OST- α/β abundance in jejunum I since the α subunit is considered to be the limiting component in conferring activity for this dimer (Sun et al.,

2007). With the translation of in vitro transporter activity through the ADAM and M-ADAM models, the variability (CV) for a given transporter was assigned for jejunum I only, and this variability was applied and propagated through all of the segments of the gastrointestinal tract (Neuhoff et al., 2013). The highest variability was also associated with OST- α/β , having CV values of 99% (Table 2), which was derived from the combination of the relative and absolute data analysis for the jejunum samples due to the limited number of samples from the absolute analysis (i.e., $n = 1$ in jejunum II). The levels for IBAT are negligible in the proximal small intestine (Gröer et al., 2013; Drozdziak et al., 2014), which may give rise to exaggerated interindividual variability due to analytical imprecision at such low levels of abundance. Hence, for this analysis the CV values were assigned from PCR-based jejunum mRNA analysis (Hilgendorf et al., 2007). In the final database, heterogeneity in absolute abundance values was found for MRP2 in the duodenum ($P = 0.049$) and ileum II ($P = 0.047$) segments. There was no between-study heterogeneity found for the other transporters within the absolute abundance database. The region-specific abundance based on the absolute abundance data set, once normalized to jejunum I, is provided in Fig. 2, A and B, with values given in Supplemental Table 3. Figure 3 shows the relative proportion of the abundance for each transporter in the final database after performing a simulation in 2000 North European Caucasians (the values are provided in Supplemental Table 4).

Relative Abundance and Combining Relative and Absolute Abundance Data Analysis. Summaries of the studies recorded and the region-specific abundances based on analysis utilizing relative abundance quantification methodology are provided for 16 transporters in the healthy Caucasian adult in Fig. 2, C and D, Supplemental Table 2B, and Table 3. With the exception of IBAT (Fig. 2, A and D), there is good consistency when comparing the region-specific abundances determined from the absolute or relative quantification methodology (Supplemental Table 3). The differences observed for this protein between methodologies may be due to the ability of the highly sensitive targeted proteomics analysis used to derive low abundances for this protein in

TABLE 2

The weighted mean, coefficient of variation, and geometric mean of total membrane protein abundance of drug transporters in the proximal jejunum (jejunum I) obtained from the meta-analysis of measurements in tissue of healthy Caucasian adults

Transporter	Mean ^a	CV	Geometric Mean ^a	Number of Samples	Number of Studies	Heterogeneity		Reference
						P	Yes/No	
		%						
ABCB1 (P-gp)	0.4	44	0.37	11	3	0.98	No	Gröer et al. (2013), Oswald et al. (2013), Drozdziak et al. (2014)
ABCC2 (MRP2)	0.86	68	0.71	11	3	0.82	No	Gröer et al. (2013), Oswald et al. (2013), Drozdziak et al. (2014)
ABCC3 (MRP3)	0.58	64	0.49	7	2	N/A ^b	N/A ^b	Gröer et al. (2013), Drozdziak et al. (2014)
ABCG2 (BCRP)	0.34	62	0.29	11	3	0.93	No	Gröer et al. (2013), Oswald et al. (2013), Drozdziak et al. (2014)
SLC10A2 (ASBT/IBAT)	0.01	43 ^c	0.01	6	1	N/A ^b	N/A ^b	Drozdziak et al. (2014)
SLC15A1 (PepT1)	3.69	41	3.41	11	3	0.92	N/A ^b	Gröer et al. (2013), Oswald et al. (2013), Drozdziak et al. (2014)
SLCO2B1 (OATP2B1)	0.4	74	0.32	11	3	0.57	No	Gröer et al. (2013), Oswald et al. (2013), Drozdziak et al. (2014)
SLC22A1 (OCT1)	0.65	49	0.58	6	1	N/A ^b	N/A ^b	Drozdziak et al. (2014)
SLC22A3 (OCT3)	0.06	74	0.05	6	1	N/A ^b	N/A ^b	Drozdziak et al. (2014)
SLC51A/B (OST- α/β)	0.47 ^d	99 ^d	0.47	1	1	N/A ^b	N/A ^b	Harwood (2015)

ASBT, apical sodium-dependent bile acid transporter; BCRP, breast cancer resistance protein; N/A, not applicable; PepT1, peptide transporter 1.

^aValues are given as picomoles per milligram of total membrane protein.

^bHeterogeneity reporting is not applicable with only one or two studies, when considering subtracting the degree of freedom component (i.e., n minus one study).

^cThe final CV value for jejunum I SLC10A2 was taken from Hilgendorf et al. (2007), based on jejunum mRNA data since it was determined that low abundance levels could give rise to inflated interindividual variability due to analytical imprecision at such low levels of expression.

^dFor OST- α/β , the mean abundance is from a distal jejunum sample and is based on the α -subunit data considering the rate-limiting component for conferring OST- α/β activity (Sun et al., 2007). Also, only a single sample was available; therefore, the CV value was obtained from a combined analysis of jejunum samples from relative and absolute data.

Fig. 2. Absolute abundance quantification of ATP-binding cassette (ABC) transporters normalized to the jejunum I segment (A) and solute carrier (SLC) family transporters (B) in all intestinal segments representing the ADAM model (C, colon; D, duodenum; I1–I4, ileum I1–I4 segments; J1 and J2, jejunum I and II segments). Relative abundance quantification of ABC transporters normalized to the jejunum I (C) and SLC transporters (D) in all intestinal segments representing the ADAM and M-ADAM models. The bars represent the weighted mean normalized abundance of each transporter. Representative values depicted in this figure are provided in Supplemental Table 3. Where no abundance data were available a zero value was assigned. This is represented in histogram B for SLC51A/B in all segments except jejunum II and ileum IV and in histogram D for SLC2A2 in all segments except duodenum, SLCO4C1 duodenum, and jejunum I and II. The values provided above the bars for SLC10A2 in histogram B represent the scaled up expression relative to the break point [//, i.e., 5] executed for these values.

the proximal jejunum (~ 0.01 pmol/mg total membrane protein) (Gröer et al., 2013; Drozdziak et al., 2014). Nevertheless, an increasing gradient of expression peaking in the terminal ileum is expected for this protein. For GLUT2, relative quantification data were only available in the duodenum; therefore, normalization to jejunum I was not possible and a relative expression value of 1 was assigned across regions. Although not shown specifically here, for the studies excluded due to ethnicity, i.e., Japanese samples (Hinoshita et al., 2000; Terada et al., 2005), the mRNA expression normalized to glyceraldehyde-3-phosphate dehydrogenase in the colon was ranked MRP3 > MRP1 = MDR1 > MRP2 (where MDR1 is defined as multidrug resistance 1), and in the final Caucasian analysis (Table 3) the ranking was similar once normalized to jejunum I with the exception of MRP1 and MDR1, showing a more pronounced difference in the Japanese data set (MRP3 > MRP1 > MDR1 > MRP2) (Hinoshita et al., 2000). While the Japanese data for the region-specific mRNA expression were fairly similar for MDR1, OCTN1, and OCT1, there was a more distally distinct decrease in expression compared to the Caucasian analysis for PepT1 (Table 3), in which there was a more uniform distribution along the small intestinal

segments (Terada et al., 2005). In the Japanese samples, OCT3 generally showed lower regional mRNA expression than Caucasians; however, its region-specific expression showed similar trends to Caucasians (Table 3) (Terada et al., 2005).

To enhance the rigor of the meta-analysis and facilitate the incorporation of an increasing number of relevant and new transporters into the ADAM and M-ADAM models, the absolute and relative quantification results for transporters were combined to obtain region-specific abundances and interindividual variability specifically for seven transporters (Tables 1 and 3). Furthermore, the final relative abundances incorporated into the ADAM and M-ADAM models are provided in Table 3. Irrespective of whether the meta-analysis for a transporter used a combined approach, or only relative quantification methodologies were available, the transporters displaying significant region-specific expression compared with the proximal jejunum (Table 3) included the following: IBAT that showed a 100-fold or more greater expression in the terminal ileum, ABCC3 (MRP3) that showed >5-fold higher expression in the colon and >2-fold higher in the duodenum, and OCTN1 and SLC22A1 (OCT1) that showed >2-fold lower expression

Jejunum I

Ileum IV

Fig. 3. Intestinal drug transporter pies. Proximal jejunum (jejunum I) ATP-binding cassette (ABC) (A) and solute carrier (SLC) and OATP (SLCO) (B). Distal ileum (ileum IV) ABC (C) and SLC and OATP (SLCO) (D). Protein abundance in the final subdatabase for each transporter family transporters as a percentage of the total abundance (in picomoles) of the region shown after performing a simulation with 2000 North European Caucasians.

in the colon. For all other evaluated transporters, the region-specific expression was relatively uniform across the segments with no transporter displaying expression greater or less than 2-fold higher than in the proximal jejunum.

Intestinal and Colon Total Membrane Protein Yield. The yields of TM protein in the intestine (TMePPI) and colon (TMePPC) were determined from three studies (Tucker et al., 2012; Drozdziak et al., 2014; Harwood, 2015). The yields based on the study by Drozdziak et al. (2014) were obtained via personal communication from Dr. Stefan Oswald (University of Greifswald, Greifswald, Germany). The data set consisted of 35 sample measurements, $n = 14$ duodenal (Tucker et al., 2012), $n = 5$ jejunum and $n = 3$ ileum (Harwood, 2015), and $n = 7$ colon (Drozdziak et al., 2014; Harwood, 2015), where the age and gender distribution (when known) was 24–72 years, with a minimum of two females. The small intestinal TM protein yield ($n = 6$) from Drozdziak et al. 2014 was provided as a lumped value covering the entire small intestinal region, as was the colon ($n = 6$) from the same study. The five jejunum samples measured from Harwood (2015) consisted of one sample from the proximal jejunum with the remainder from the distal jejunum (one

female; 41–62 years). Since each study did not contain specific TM protein yield data for each segment, the capacity to determine TMePPI and TMePPC required several conversions and assumptions in order to estimate yields in regions that were not measured experimentally (Supplemental Material, see the section on the total membrane protein yield). The weighted mean ($\pm$ S.D.) values from the three studies were 2737 ± 1807 mg for TMePPI and 112 ± 37 mg for TMePPC, which were used to calculate the absolute abundance of protein in picomoles per milligram TM protein from the meta-analysis to picomole concentrations.

Discussion

The heightened recognition that PBPK models play a role in evaluating the mechanisms responsible for drug pharmacokinetics at industrial and regulatory levels has driven the demand to quantify key drug and physiologic elements precisely and accurately in PBPK models. The relative expression factor (REF) approach provided a means to scale transporter activity from cell monolayers in various

TABLE 3
Final region-specific abundances along the gastrointestinal tract normalized to jejunum I based on relative abundance quantification or by combining abundance data obtained from relative and absolute quantification methodology

Protein	ADAM Model Segment (Sample Number Quantified Is Given in Parentheses)								Reference
	Duodenum	Jejunum I ^a	Jejunum II	Ileum I	Ileum II	Ileum III	Ileum IV	Colon	
ABCB1 (P-gp) ^{b,c}	0.51 (31)	1 (9)	1.46 (8)	1.50 (42)	1.51 (42)	1.52 (42)	1.51 (42)	0.57 (27)	See Table 2 in Harwood et al. (2013) for references Fromm et al. (2000), Albernann et al. (2005), Zimmermann et al. (2005), Berggren et al. (2007), Blokzijl et al. (2007), Bourguine et al. (2012), Drozdziak et al. (2014)
ABCC1 (MRP1) ^b	0.45 (37)	1 (9)	0.88 (9)	0.86 (37)	0.86 (37)	0.89 (37)	0.89 (37)	0.93 (50)	
ABCC2 (MRP2) ^{b,c}	1.41 (71)	1 (4)	1 (4)	0.60 (41)	0.60 (41)	0.60 (41)	0.60 (41)	0.02 (26)	See Table 2 in Harwood et al. (2013) for references Zimmermann et al. (2005), Englund et al. (2006), Seithel et al. (2006), Bourguine et al. (2012), Gröer et al. (2013), Drozdziak et al. (2014)
ABCC3 (MRP3)	2.15 (29)	1 (16)	0.89 (16)	1.54 (35)	1.54 (35)	1.60 (35)	1.60 (35)	5.95 (35)	
ABCC4 (MRP4) ^b	1.02 (15)	1 (6)	1.22 (6)	1.71 (19)	1.71 (19)	1.20 (19)	1.20 (19)	1.76 (19)	Zimmermann et al. (2005), Bourguine et al. (2012), Drozdziak et al. (2014)
ABCG2 (BCRP) ^{b,c}	0.47 (45)	1 (14)	1 (45)	0.59 (45)	0.59 (45)	0.59 (45)	0.59 (45)	0.13 (35)	
SLC2A2 (GLUT2) ^b	1 (15)	1 (0) ^d	1 (0) ^d	1 (0) ^d	1 (0) ^d	1 (0) ^d	1 (0) ^d	1 (0) ^d	See Table 2 in Harwood et al. (2013) for references Wilder-Smith et al. (2014)
SLC10A2 (ASBT/IBAT)	16.49 (30)	1 (6)	4 (6)	98.44 (59)	98.44 (59)	109.18 (59)	108.00 (59)	1.10 (56)	
SLC15A1 (PEPT1)	0.94 (35)	1 (20)	1.06 (20)	1.23 (67)	1.23 (67)	1.24 (67)	1.24 (67)	0.03 (63)	(2012), Gröer et al. (2013), Drozdziak et al. (2014) Ziegler et al. (2002), Englund et al. (2006), Seithel et al. (2006), Meier et al. (2007), Wojtal et al. (2009), Bourguine et al. (2012), Gröer et al. (2013), Oswald et al. (2013), Drozdziak et al. (2014)
SLC16A1 (MCT1) ^b	1.25 (17)	1 (13)	1 (13)	1.29 (20)	1.29 (20)	1.29 (20)	1.29 (20)	4.72 (26)	
SLC20B1 (OATP2B1)	0.73 (30)	1 (20)	0.94 (20)	1.28 (76)	1.28 (76)	1.28 (76)	1.28 (76)	1.06 (58)	Gill et al. (2005), Englund et al. (2006), Seithel et al. (2006), Bourguine et al. (2012) Englund et al. (2006), Seithel et al. (2006), Meier et al. (2007), Wojtal et al. (2009), Bourguine et al. (2012), Gröer et al. (2013), Oswald et al. (2013), Drozdziak et al. (2014)
SLC22A1 (OCT1)	1 (0) ^d	1 (6)	1 (0) ^d	1 (3) ^e	1 (3) ^e	1 (3) ^e	1 (3) ^e	1 (3) ^e	
SLC22A3 (OCT3)	1.19 (6)	1 (6)	1.11 (6)	1.08 (12)	1.08 (12)	1.23 (12)	1.23 (12)	1.88 (9)	Bourguine et al. (2012), Gröer et al. (2013), Drozdziak et al. (2014) Meier et al. (2007), Wojtal et al. (2009), Bourguine et al. (2012), Gröer et al. (2012), Girardin et al. (2012), Drozdziak et al. (2014)
SLC22A4 (OCTN1) ^b	0.46 (16)	1 (6)	0.63 (6)	0.78 (51)	0.78 (51)	0.80 (51)	0.80 (51)	0.24 (49)	
SLC51A/B (OST- α / β) ^f	0.56 (6)	1 (6)	1.89 (7)	1.08 (40)	1.08 (40)	0.93 (40)	0.93 (41)	0.71 (6)	Renner et al. (2008), Drozdziak et al. (2014), Harwood (2015) Renner et al. (2008), Drozdziak et al. (2014), Harwood (2015)
SLC51B (OST- β) ^f	0.6 (6)	1.19 (6)	1.16 (9)	1.01 (40)	1.01 (40)	1 (40)	1 (41)	0.33 (6)	

ASBT, apical sodium-dependent bile acid transporter; BCRP, breast cancer resistance protein; MCT1, monocarboxylate transporter 1; PEPT1, peptide transporter 1.

^aFixed value of 1; jejunum I was fixed to 1 as the final value; however, prior to normalization a weighted mean relative expression was calculated across samples with the potential for CV generation, hence the sample number provided.

^bWhere only relative abundance data were available.

^cFinal values not updated from those previously reported (Harwood et al., 2013) since the region-specific absolute abundance values in Supplemental Table 3 were similar.

^dWhere samples were not quantified within a given region a relative abundance value of 1 was assumed.

^eSince there were no jejunum I values available to normalize the ileum and colon abundances to the relative expression for these segments, the value was set to 1.

^fUsed OST- α values from relative and absolute combined analysis—for completeness the OST- β segmental relative abundance values are given in the last row of the table.

regions of the intestine (Neuhoff et al., 2013). Although practical, these models are not as sophisticated as those for P450s, in which the intersystem extrapolation factor scalar corrects for activity differences per unit of enzymes in the liver versus recombinant systems (Proctor et al., 2004). The increasing utilization of methodologies to quantitatively determine a protein's absolute abundance within a biologic system has led to efforts from developers of PBPK model platforms to harness these data within a physiologic framework. The ISEF-T approach permits transporter-specific scaling of *in vitro* kinetics based on a protein's molar concentration within an individual's organ (Burt et al., 2016). Given the increasing availability of region-specific intestinal transporter expression data from the relative and absolute quantification approaches, a rigorous meta-analysis is provided to obtain region-specific transporter abundances and variability in healthy adult Caucasians.

Literary evidence was evaluated to prioritize intestinal transporters involved in drug disposition for inclusion into the meta-analysis. To accurately construct PBPK models that can assess the impact of transporter proteins, substantiating their intestinal expression, function, and localization on the enterocyte plasma membrane are imperative. *In vitro* studies were required to assess the plasma membrane localization and functional aspects for certain transporters, while intestinal transporter expression was confirmed primarily via immunoblotting, quantitative proteomics, immunohistochemistry, and mRNA expression. The clinical pharmacokinetic relevance was also considered (http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf; <https://www.fda.gov/downloads/drugs/guidances/ucm292362.pdf>) (Zamek-Gliszczynski et al., 2018). For the majority of transporters (Table 1), intestinal protein expression was unequivocal (P-gp, MRP2, MRP3, breast cancer resistance protein (BCRP), OATP2B1, IBAT, PepT1, monocarboxylate transporter 1, OCT1, and OCT3). For MRP1, OCTN1, MRP4, and OST- α/β , where proteomics data were limited to a single study or intestinal region (Harwood, 2015; Wiśniewski et al., 2015; Nakamura et al., 2016), supporting evidence related to other protein quantification methods or mRNA expression was sought prior to ranking for inclusion. For OATP4C1, its capacity to transport the P-gp probe digoxin across the basolateral membrane of the renal proximal tubule cell is implicated (Mikkaichi et al., 2004), while transcriptional information supports potential expression in the small intestine and immunohistochemistry demonstrates basolateral membrane expression in colon enterocytes (Hilgendorf et al., 2007; Bourguine et al., 2012; Kleberg et al., 2012). OATP1A2 (one of the initial 52 transporters evaluated) is of potential pharmacokinetic relevance; however, several studies show intestinal mRNA and protein levels are absent or negligible (Supplemental Table 1). Hence, this transporter is not included in the final meta-analysis. GLUT2 is considered in the model as a potential drug target for obesity and diabetes since jejunal GLUT2 is highly abundant in morbidly obese individuals (Miyachi et al., 2016). In obesity, GLUT2 translocates from the enterocyte's basolateral membrane in healthy individuals to the apical membrane (Ait-Omar et al., 2011). Understanding a transporter's location and function is crucial to constructing the appropriate model structure and algorithms to accurately scale transporter activity. There is conflicting information regarding the enterocyte localization of OCT1, in which earlier studies implicated the lateral/basolateral membrane localization (Müller et al., 2005; Giacomini et al., 2010) but a later study that combined immunocytochemistry and functional transporter assays using the OCT1-specific substrate pentamidine concluded that apical uptake predominated (Han et al., 2013). Hence, OCT1 is assigned as an apical membrane uptake transporter (Table 1). The enterocyte localization of OATP2B1 has also been under scrutiny recently (Keiser et al., 2017).

Early studies implicated apical localization on human intestinal sections and Caco-2 cells (Kobayashi et al., 2003; Sai et al., 2006). However, recent proteomic investigations demonstrated markedly higher OATP2B1 expression in basolateral compared with apical membrane fractions; however, accompanying immunostaining revealed less emphasis on basolateral localization (Keiser et al., 2017). Given these findings, OATP2B1 expression in both apical and basolateral membranes is plausible, thus OATP2B1 is assigned as an apical uptake transporter (Table 1). However, the switching of transporter localization and function in the model is possible, thus OATP2B1 could represent a basolateral uptake transporter.

To ascertain region-specific absolute transporter abundances via meta-analysis for the prioritized 16 transporters, a complete database was compiled cataloging 3374 measurements across all intestinal regions. To define the healthy Caucasian adult intestinal transporter expression a refined database was curated, where several exclusion criteria were applied such that the largest proportion of measurements excluded were that of non-healthy samples (Fig. 1). Disease can affect transporter expression (Evers et al., 2018); therefore, distinguishing between those samples that are directly affected by disease is critical. However, the challenge with curating such a data set is that a routine means of obtaining intestinal samples to quantify protein expression is from individual's undergoing surgical intervention for an array of complications. In such cases, if studies classified their samples as macroscopically normal it was assumed that the tissue's protein expression was unaffected by the disease, thus these measurements were incorporated into the refined database.

The ADAM and M-ADAM models scale intestinal transporter activity in a region-specific manner after normalization against the reference jejunum I segment in both the ISEF-T and REF approaches (Neuhoff et al., 2013). Therefore, the primary goal is to determine the jejunum I absolute transporter protein abundance and its associated interindividual variability (Table 2). For certain transporters, it was necessary to obtain the CV values from absolute and relative data sets, since there were insufficient jejunum-based absolute abundance quantifications (OST- α/β) or jejunum-mRNA quantification was being considered (IBAT). For all other intestinal segments where data were available, the weighted mean transporter abundances were determined and normalization to the jejunum I abundance (picomoles per milligram TM protein) was performed. Between-study heterogeneity was not as evident as in the healthy Caucasian adult liver absolute abundance meta-analysis (Burt et al., 2016), with MRP2 being the only transporter displaying this tendency in two segments. This may be due to less biologic variability between the studies or lower sample numbers available to distinguish heterogeneity than for the liver. Due to the limited availability of measurements that can be directly attributed to a given donor, it was not possible to perform any correlation analysis with respect to age and gender.

Although performing region-specific meta-analysis using studies quantifying transporter protein or mRNA expression using relative quantification techniques cannot directly inform us of the absolute levels of transporter abundances within a sample, it does provide a relatively large number of measurements, which provide robust region-specific expression information for each transporter after normalization to jejunum I when combined with the absolute data set. Except for IBAT, the relative or absolute quantification techniques showed limited region-specific transporter differences. This provided us with the confidence to use both absolute and relative data sets in order to obtain the final region-specific abundances for incorporation into a healthy Caucasian population. Alone, the relative expression data set was instrumental in providing region-specific expression data for six transporters (Tables 1

and 3), allowing the REF approach to be employed even if absolute abundances were not available.

Absolute abundance data were available from whole tissue homogenate, TM fractions, and plasma membrane fractions. However, only data obtained from TM fractions were included in the final database, since corresponding protein yield values enabling the conversion of abundance values to picomoles per transporter/intestinal segment are reported here for the first time. Derivations of the intestinal (TMePPI = 2737 ± 1807 mg) and colonic (TMePPC = 112 ± 37 mg) total membrane protein yields were based on three studies in which the primary focus of each study was not the determination of these parameters (Tucker et al., 2012; Drozdziak et al., 2014; Harwood, 2015). Therefore, the application of several assumptions based on determination of intestinal/mucosal tissue yields (Paine et al., 1997) and intestinal mucosal cylindrical surface areas facilitated the determination of the yields being dependent on whether the mucosa or enterocytes specifically were processed (Supplemental Material, see the section on the total membrane protein yield). The TMePPI is in reasonable agreement with the small intestine microsomal protein yield of 2978 mg, which is anticipated given the methodological similarity in obtaining microsomes (Paine et al., 1997) or TM fractions (Tucker et al., 2012) using differential centrifugation. It is difficult to gauge the physiologic plausibility of the TMePPC since there are no equivalent colonic microsomal data published for comparative purposes; however, a lower TMePPC is expected than TMePPI, given the highly folded structure of the small intestinal mucosa compared with the colon. Further dedicated studies are sought to investigate intestinal membrane protein yield.

This is the first in-depth systematic analysis of intestinal region-specific transporter expression based on absolute abundance quantification methods. The expression data derived herein provide additional flexibility in modeling region-specific active transport processes for 16 transporters expressed in the enterocyte utilizing both relative (REF) and absolute abundance (ISEF-T) scaling approaches. To use the ISEF-T approach, increasing focus on measuring in vitro transporter kinetics combined with absolute transporter abundances (Meng et al., 2017a,b) is required. Routine updates to the database are required when applicable data become available (Drozdziak et al., 2018), and further studies are warranted to enhance our ability to translate absolute abundance quantification data into mechanistic models, while similar analyses are required for other ethnicities and disease models.

Acknowledgments

We thank Dr. Stefan Oswald (University of Greifswald, Greifswald, Germany) for personally communicating the total membrane protein yield data from the Drozdziak et al., (2014) study, Dr. Iain Gardner for productive discussions, and Dr. Gopal Pawar (formerly of Certara UK Ltd., Simcyp Division) for assisting with the initial selection of transporters for inclusion in the database. We also thank Eleanor Savill for assistance in formatting the manuscript for submission.

Authorship Contributions

Participated in research design: Harwood, Zhang, Pathak, Neuhoff.

Conducted experiments: Harwood, Zhang, Pathak, Neuhoff.

Performed data analysis: Harwood, Zhang, Pathak, Neuhoff.

Wrote or contributed to the writing of the manuscript: Harwood, Zhang, Pathak, Neuhoff.

References

Ait-Omar A, Monteiro-Sepulveda M, Poitou C, Le Gall M, Cottillard A, Gilet J, Garbin K, Houllier A, Chateau D, Lacombe A, et al. (2011) GLUT2 accumulation in enterocyte apical and intracellular membranes: a study in morbidly obese human subjects and ob/ob and high fat-fed mice. *Diabetes* **60**:2598–2607.

Albermann N, Schmitz-Winnenthal FH, Z'raggen K, Volk C, Hoffmann MM, Haeftel WE, and Weiss J (2005) Expression of the drug transporters *MDR1/ABCB1*, *MRP1/ABCC1*,

MRP2/ABCC2, *BCRP/ABCG2*, and *PXR* in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. *Biochem Pharmacol* **70**:949–958.

Berggren S, Gall C, Wollnitz N, Ekelund M, Karlsson U, Hoogstraate J, Schrenk D, and Lennernäs H (2007) Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. *Mol Pharm* **4**:252–257.

Blokzijl H, Vander Borghst S, Bok LI, Libbrecht L, Geuken M, van den Heuvel FA, Dijkstra G, Roskams TA, Moshage H, Jansen PL, et al. (2007) Decreased P-glycoprotein (P-gp/MDR1) expression in inflamed human intestinal epithelium is independent of PXR protein levels. *Inflamm Bowel Dis* **13**:710–720.

Bourguin J, Billaut-Laden I, Hapillon M, Lo-Guidice JM, Maunoury V, Imbenotte M, and Broly F (2012) Gene expression profiling of systems involved in the metabolism and the disposition of xenobiotics: comparison between human intestinal biopsy samples and colon cell lines. *Drug Metab Dispos* **40**:694–705.

Brück S, Strohmeyer J, Busch D, Drozdziak M, and Oswald S (2017) Caco-2 cells—expression, regulation and function of drug transporters compared with human jejunal tissue. *Biopharm Drug Dispos* **38**:115–126.

Burt HJ, Riedmaier AE, Harwood MD, Crewe HK, Gill KL, and Neuhoff S (2016) Abundance of hepatic transporters in Caucasians: a meta-analysis. *Drug Metab Dispos* **44**:1550–1561.

César-Razquin A, Snijder B, Frappier-Brinton T, Isserlin R, Gyimesi G, Bai X, Reithmeier RA, Hepworth D, Hediger MA, Edwards AM, et al. (2015) A call for systematic research on solute carriers. *Clin Lett* **162**:478–487.

de Zwart L, Snoeys J, De Jong J, Sukbunthorn J, Mannaert E, and Monshouwer M (2016) Ibrutinib dosing strategies based on interaction potential of CYP3A4 perpetrators using physiologically based pharmacokinetic modeling. *Clin Pharmacol Ther* **100**:548–557.

Drozdziak M, Busch D, Lapczuk J, Müller J, Ostrowski M, Kurzwski M, and Oswald S (2018) Protein abundance of clinically relevant drug-metabolizing enzymes in the human liver and intestine: a comparative analysis in paired tissue specimens. *Clin Pharmacol Ther* **104**:515–524.

Drozdziak M, Gröer C, Penski J, Lapczuk J, Ostrowski M, Lai Y, Prasad B, Unadkat JD, Siegmund W, and Oswald S (2014) Protein abundance of clinically relevant multidrug transporters along the entire length of the human intestine. *Mol Pharm* **11**:3547–3555.

Englund G, Rorsman F, Rönblom A, Karlsson U, Lazorova L, Gråsjö J, Kindmark A, and Artursson P (2006) Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with caco-2 cells. *Eur J Pharm Sci* **29**:269–277.

Evers R, Piquette-Miller M, Polli JW, Russel FGM, Sprowl JA, Tohyama K, Ware JA, de Wildt SN, Xie W, and Brouwer KLR; International Transporter Consortium (2018) Disease-associated changes in drug transporters may impact the pharmacokinetics and/or toxicity of drugs: a white paper from the International Transporter Consortium. *Clin Pharmacol Ther* **104**:900–915.

Fromm MF, Kauffmann HM, Fritz P, Burk O, Kroemer HK, Wazark RW, Eichelbaum M, Siegmund W, and Schrenk D (2000) The effect of rifampin treatment on intestinal expression of human MRP transporters. *Am J Pathol* **157**:1575–1580.

Gertz M, Harrison A, Houston JB, and Galetin A (2010) Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. *Drug Metab Dispos* **38**:1147–1158.

Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, et al.; International Transporter Consortium (2010) Membrane transporters in drug development. *Nat Rev Drug Discov* **9**:215–236.

Gill RK, Saksena S, Alrefai WA, Sarwar Z, Goldstein JL, Carroll RE, Ramaswamy K, and Dudeja PK (2005) Expression and membrane localization of MCT isoforms along the length of the human intestine. *Am J Physiol Cell Physiol* **289**:C846–C852.

Girardin M, Dionne S, Goyette P, Rioux J, Bitton A, Elmirani I, Charlebois P, Qureshi I, Levy E, and Seidman EG (2012) Expression and functional analysis of intestinal organic cation/L-carnitine transporter (OCTN) in Crohn's disease. *J Crohn's Colitis* **6**:189–197.

Gröer C, Brück S, Lai Y, Paulick A, Busemann A, Heidecke CD, Siegmund W, and Oswald S (2013) LC-MS/MS-based quantification of clinically relevant intestinal uptake and efflux transporter proteins. *J Pharm Biomed Anal* **85**:253–261.

Guo Y, Chu X, Parrott NJ, Brouwer KLR, Hsu V, Nagar S, Matsson P, Sharma P, Snoeys J, Sugiyama Y, et al.; International Transporter Consortium (2018) Advancing predictions of tissue and intracellular drug concentrations using in vitro, imaging and physiologically based pharmacokinetic modeling approaches. *Clin Pharmacol Ther* **104**:865–889.

Han TK, Everett RS, Proctor WR, Ng CM, Costales CL, Brouwer KL, and Thakker DR (2013) Organic cation transporter 1 (OCT1/mOct1) is localized in the apical membrane of Caco-2 cell monolayers and enterocytes. *Mol Pharmacol* **84**:182–189.

Harwood MD (2015) *Towards a fully mechanistic prediction of oral drug absorption: investigating intestinal transporter abundance and function relationships*. Ph.D. thesis, Faculty of Medical and Human Sciences, The University of Manchester, Manchester, UK.

Harwood MD, Achour B, Russell MR, Carlson GL, Warhurst G, and Rostami-Hodjegan A (2015) Application of an LC-MS/MS method for the simultaneous quantification of human intestinal transporter proteins absolute abundance using a QconCAT technique. *J Pharm Biomed Anal* **110**:27–33.

Harwood MD, Neuhoff S, Carlson GL, Warhurst G, and Rostami-Hodjegan A (2013) Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption. *Biopharm Drug Dispos* **34**:2–28.

Heikkinen AT, Lignat F, Cutler P, and Parrott N (2015) The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development. *Proteomics Clin Appl* **9**:732–744.

Herrera-Ruiz D, Wang Q, Gudmundsson OS, Cook TJ, Smith RL, Faria TN, and Knipp GT (2001) Spatial expression patterns of peptide transporters in the human and rat gastrointestinal tracts, Caco-2 in vitro cell culture model, and multiple human tissues. *AAPS PharmSci* **3**:E9.

Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, and Karlsson J (2007) Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. *Drug Metab Dispos* **35**:1333–1340.

Hinoshita E, Uchiyama T, Taguchi K, Kinukawa N, Tsuneyoshi M, Maehara Y, Sugimachi K, and Kuwano M (2000) Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. *Clin Cancer Res* **6**:2401–2407.

Hruz P, Zimmermann C, Gutmann H, Degen L, Beuers U, Terracciano L, Drewe J, and Beglinger C (2006) Adaptive regulation of the ileal apical sodium dependent bile acid transporter (ASBT) in patients with obstructive cholestasis. *Gut* **55**:395–402.

Jamei M, Bajot F, Neuhoff S, Barter Z, Yang J, Rostami-Hodjegan A, and Rowland-Yeo K (2014) A mechanistic framework for in vitro-in vivo extrapolation of liver membrane

- transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine. *Clin Pharmacokinet* **53**:73–87.
- Jamei M, Turner D, Yang J, Neuhoﬀ S, Polak S, Rostami-Hodjegan A, and Tucker G (2009) Population-based mechanistic prediction of oral drug absorption. *AAPS J* **11**:225–237.
- Jones HM, Barton HA, Lai Y, Bi YA, Kimoto E, Kempshall S, Tate SC, El-Kattan A, Houston JB, Galetin A, et al. (2012) Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. *Drug Metab Dispos* **40**:1007–1017.
- Jones HM, Chen Y, Gibson C, Heimbach T, Parrott N, Peters SA, Snoeys J, Upreti VV, Zheng M, and Hall SD (2015) Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. *Clin Pharmacol Ther* **97**:247–262.
- Keiser M, Kaltheuner L, Wildberg C, Müller J, Grube M, Partecke LI, Heidecke CD, and Oswald S (2017) The organic anion-transporting peptide 2B1 is localized in the basolateral membrane of the human jejunum and caco-2 monolayers. *J Pharm Sci* **106**:2657–2663.
- Kim HR, Park SW, Cho HJ, Chae KA, Sung JM, Kim JS, Landowski CP, Sun D, Abd El-Aty AM, Amidon GL, et al. (2007) Comparative gene expression profiles of intestinal transporters in mice, rats and humans. *Pharmacol Res* **56**:224–236.
- Kleberg K, Jensen GM, Christensen DP, Lundh M, Grunnet LG, Knuhtsen S, Poulsen SS, Hansen MB, and Bindlev N (2012) Transporter function and cyclic AMP turnover in normal colonic mucosa from patients with and without colorectal neoplasia. *BMC Gastroenterol* **12**:78.
- Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, and Tamai I (2003) Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. *J Pharmacol Exp Ther* **306**:703–708.
- Landowski CP, Sun D, Foster DR, Menon SS, Barnett JL, Welage LS, Ramachandran C, and Amidon GL (2003) Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. *J Pharmacol Exp Ther* **306**:778–786.
- Meier Y, Eloranta JJ, Darimont J, Ismail MG, Hiller C, Fried M, Kullak-Ublick GA, and Vavricka SR (2007) Regional distribution of solute carrier mRNA expression along the human intestinal tract. *Drug Metab Dispos* **35**:590–594.
- Meng Z, Ellens H, and Bentz J (2017a) Extrapolation of elementary rate constants of P-glycoprotein-mediated transport from MDCKII-hMDR1-NKI to caco-2 cells. *Drug Metab Dispos* **45**:190–197.
- Meng Z, Le Marchand S, Agnani D, Szapacs M, Ellens H, and Bentz J (2017b) Microvilli morphology can affect efflux active P-glycoprotein in confluent MDCKII -hMDR1-NKI and caco-2 cell monolayers. *Drug Metab Dispos* **45**:145–151.
- Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutani H, Okada M, Chaki T, Masuda S, Tokui T, Eto N, et al. (2004) Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. *Proc Natl Acad Sci USA* **101**:3569–3574.
- Miyauchi E, Tachikawa M, Declèves X, Uchida Y, Bouillot JL, Poitou C, Oppert JM, Mouly S, Bergmann JF, Terasaki T, et al. (2016) Quantitative atlas of cytochrome P450, UDP-glucuronosyltransferase, and transporter proteins in jejunum of morbidly obese subjects. *Mol Pharm* **13**:2631–2640.
- Müller J, Lips KS, Metzner L, Neubert RH, Koepsell H, and Brandsch M (2005) Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). *Biochem Pharmacol* **70**:1851–1860.
- Nakamura K, Hirayama-Kurogi M, Ito S, Kuno T, Yoneyama T, Obuchi W, Terasaki T, and Ohtsuki S (2016) Large-scale multiplex absolute protein quantification of drug-metabolizing enzymes and transporters in human intestine, liver, and kidney microsomes by SWATH-MS: comparison with MRM/MS and HR-MRM/MS. *Proteomics* **16**:2106–2117.
- Neuhoﬀ S, Yeo KR, Barter Z, Jamei M, Turner DB, and Rostami-Hodjegan A (2013) Application of permeability-limited physiologically-based pharmacokinetic models: part I-digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux. *J Pharm Sci* **102**:3145–3160.
- Oswald S, Gröer C, Drozdick M, and Siegmund W (2013) Mass spectrometry-based targeted proteomics as a tool to elucidate the expression and function of intestinal drug transporters. *AAPS J* **15**:1128–1140.
- Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, and Thummel KE (1997) Characterization of interintestinal and intrainestinal variations in human CYP3A-dependent metabolism. *J Pharmacol Exp Ther* **283**:1552–1562.
- Pan Y, Hsu V, Grimstein M, Zhang L, Arya V, Sinha V, Grillo JA, and Zhao P (2016) The application of physiologically based pharmacokinetic modeling to predict the role of drug transporters: scientific and regulatory perspectives. *J Clin Pharmacol* **56** (Suppl 7):S122–S131.
- Perrett HF, Barter ZE, Jones BC, Yamazaki H, Tucker GT, and Rostami-Hodjegan A (2007) Disparity in holoprotein/apoprotein ratios of different standards used for immunoquantification of hepatic cytochrome P450 enzymes. *Drug Metab Dispos* **35**:1733–1736.
- Proctor NJ, Tucker GT, and Rostami-Hodjegan A (2004) Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. *Xenobiotica* **34**:151–178.
- Renner O, Harsch S, Strohmeyer A, Schimmel S, and Stange EF (2008) Reduced ileal expression of OAT α -OAT β in non-obese gallstone disease. *J Lipid Res* **49**:2045–2054.
- Sai Y, Kaneko Y, Ito S, Mitsuoka K, Kato Y, Tamai I, Artursson P, and Tsuji A (2006) Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal caco-2 cells. *Drug Metab Dispos* **34**:1423–1431.
- Seithel A, Karlsson J, Hilgendorf C, Björquist A, and Ungell AL (2006) Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells. *Eur J Pharm Sci* **28**:291–299.
- Seward DJ, Koh AS, Boyer JL, and Ballatori N (2003) Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OAT α -OAT β . *J Biol Chem* **278**:27473–27482.
- Shebley M, Sandhu P, Emami Riedmaier A, Jamei M, Narayanan R, Patel A, Peters SA, Reddy VP, Zheng M, de Zwart L, et al. (2018) Physiologically based pharmacokinetic model qualification and reporting procedures for regulatory submissions: a consortium perspective. *Clin Pharmacol Ther* **104**:88–110.
- Sun AQ, Balasubramanian N, Xu K, Liu CJ, Ponamgi VM, Liu H, and Suchy FJ (2007) Protein-protein interactions and membrane localization of the human organic solute transporter. *Am J Physiol Gastrointest Liver Physiol* **292**:G1586–G1593.
- Terada T, Shimada Y, Pan X, Kishimoto K, Sakurai T, Doi R, Onodera H, Katsura T, Imamura M, and Inui K (2005) Expression profiles of various transporters for oligopeptides, amino acids and organic ions along the human digestive tract. *Biochem Pharmacol* **70**:1756–1763.
- Thibault R, De Coppel P, Daly K, Bourreille A, Cuff M, Bonnet C, Mosnier JF, Galmiche JP, Shirazi-Beechey S, and Segain JP (2007) Down-regulation of the monocarboxylate transporter 1 is involved in butyrate deficiency during intestinal inflammation. *Gastroenterology* **133**:1916–1927.
- Tucker TGHA, Milne AM, Fournel-Gigleux S, Fenner KS, and Coughtrie MWH (2012) Absolute immunoquantification of the expression of ABC transporters P-glycoprotein, breast cancer resistance protein and multidrug resistance-associated protein 2 in human liver and duodenum. *Biochem Pharmacol* **83**:279–285.
- Vaessen SF, van Lipzig MM, Pieters RH, Krul CA, Wortelboer HM, and van de Steeg E (2017) Regional expression levels of drug transporters and metabolizing enzymes along the pig and human intestinal tract and comparison with Caco-2 cells. *Drug Metab Dispos* **45**:353–360.
- Varma MV, Lai Y, Feng B, Litchfield J, Goosen TC, and Bergman A (2012) Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. *Pharm Res* **29**:2860–2873.
- Wagner C, Pan Y, Hsu V, Grillo JA, Zhang L, Reynolds KS, Sinha V, and Zhao P (2015) Predicting the effect of cytochrome P450 inhibitors on substrate drugs: analysis of physiologically based pharmacokinetic modeling submissions to the US Food and Drug Administration. *Clin Pharmacokinet* **54**:117–127.
- Wilder-Smith CH, Li X, Ho SS, Leong SM, Wong RK, Koay ES, and Ferraris RP (2014) Fructose transporters GLUT5 and GLUT2 expression in adult patients with fructose intolerance. *United European Gastroenterol J* **2**:14–21.
- Wiśniewski JR, Duś-Zachniewicz K, Ostasiewicz P, Ziolkowski P, Rakus D, and Mann M (2015) Absolute proteome analysis of colorectal mucosa, adenoma, and cancer reveals drastic changes in fatty acid metabolism and plasma membrane transporters. *J Proteome Res* **14**:4005–4018.
- Wojtal KA, Eloranta JJ, Hruz P, Gutmann H, Drewe J, Staumann A, Beglinger C, Fried M, Kullak-Ublick GA, and Vavricka SR (2009) Changes in mRNA expression levels of solute carrier transporters in inflammatory bowel disease patients. *Drug Metab Dispos* **37**:1871–1877.
- Yamazaki S, Loi CM, Kimoto E, Costales C, and Varma MV (2018) Application of physiologically based pharmacokinetic modeling in understanding bosutinib drug-drug interactions: importance of intestinal P-glycoprotein. *Drug Metab Dispos* **46**:1200–1211.
- Zamek-Gliszczynski MJ, Taub ME, Chothe PP, Chu X, Giacomini KM, Kim RB, Ray AS, Stocker SL, Unadkat JD, Wittwer MB, et al.; International Transporter Consortium (2018) Transporters in drug development: 2018 ITC recommendations for transporters of emerging clinical importance. *Clin Pharmacol Ther* **104**:890–899.
- Ziegler TR, Fernández-Estívariz C, Gu LH, Bazargan N, Umeakunne K, Wallace TM, Diaz EE, Rosado KE, Pascal RR, Galloway JR, et al. (2002) Distribution of the H+/peptide transporter PepT1 in human intestine: up-regulated expression in the colonic mucosa of patients with short-bowel syndrome. *Am J Clin Nutr* **75**:922–930.
- Zimmermann C, Gutmann H, Hruz P, Gutzwiller JP, Beglinger C, and Drewe J (2005) Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract. *Drug Metab Dispos* **33**:219–224.

Address correspondence to: Dr. Matthew D. Harwood, Certara UK Ltd, Simcyp Division, Level 2-Acero, 1 Concourse Way, Sheffield S1 2BJ, UK. E-mail: matthew.harwood@certara.com